Embecta Stock

$11.45

2.39% today

NYSE, Jul 28, 06:51 pm CET

ISIN

US29082K1051

Symbol

EMBC

Reports

Quarter | Annual

Index

S&P SmallCap 600

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Embecta Stock price

$11.73

-35.27 75.04% 5Y

NYSE, Closing price Fri, Jul 25 2025

+0.35 3.08%

ISIN

US29082K1051

Symbol

EMBC

Reports

Quarter | Annual

Index

S&P SmallCap 600

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$685.5m

Enterprise Value

$2.0b

Net debt

$1.3b

Cash

$209.3m

Shares outstanding

58.3m

Valuation (TTM | estimate)

P/E

13.0 | 4.1

P/S

0.6 | 0.6

EV/Sales

1.9 | 1.8

EV/FCF

51.1

P/B

negative

Dividends

DPS

$0.60

Yield 1Y | 5Y

5.1% | 1.2%

Growth 1Y | 5Y

0.0% | -

Payout 1Y | 3Y

44.8% | 20.9%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$1.1b | $1.1b

EBITDA

$328.4m | $416.5m

EBIT

$291.6m | $337.6m

Net Income

$52.8m | $167.8m

Free Cash Flow

$39.7m

Growth (TTM | estimate)

Revenue

-4.7% | -1.6%

EBITDA

65.4% | 29.7%

EBIT

80.2% | 18.5%

Net Income

-24.8% | 114.3%

Free Cash Flow

322.3%

Financial Health

Equity Ratio

-57.4%

Return on Equity

-10.6%

ROCE

33.9%

ROIC

33.6%

Debt/Equity

-2.1

EPS

$0.9

FCF per Share

$0.7

Short interest

8.5%

Employees

Rev per Employee

$510.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Embecta Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Embecta forecast:

4x Hold

44%

4x Sell

44%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Embecta forecast:

Buy

11%

Hold

44%

Sell

44%

Analyst Estimates with Stock Price Targets

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1,080 1,080	5% 5% 100%
- Direct Costs	382 382	2% 2% 35%
Gross Profit	698 698	6% 6% 65%
- Selling and Administrative Expenses	343 343	6% 6% 32%
- Research and Development Expense	53 53	37% 37% 5%
EBITDA	328 328	65% 65% 30%
- Depreciation and Amortization	37 37	0% 0% 3%
EBIT (Operating Income) EBIT	292 292	80% 80% 27%
Net Profit	53 53	25% 25% 5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Embecta Stock News

Neutral

GlobeNewsWire

●

4 days ago

embecta to Report Fiscal Third Quarter 2025 Financial Results

PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Easter...

Neutral

GlobeNewsWire

●

2 months ago

embecta to Participate in Investor Events

PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

Neutral

GlobeNewsWire

●

2 months ago

embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day

PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan (“LRP”).

More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office	United States
CEO	Devdatt Kurdikar
Employees	2,200
Founded	1924
Website	www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now